Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis Diovan Heart Failure Indication Covers 1.2-2.5 Million Patients

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Novartis will be targeting 1.2 mil. to 2.5 mil. patients with the August 14 approval of Diovan for "treatment of heart failure (NYHA class II-IV) in patients who are intolerant of angiotensin converting enzyme inhibitors."

You may also be interested in...

Atacand For CHF: Can AstraZeneca CHARM FDA Into ACE Combo Approval?

AstraZeneca’s upcoming Atacand sNDA for use in heart failure will likely raise issues about conflicting data on another agent in the same class.

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts